FUSION is a clinical study of an investigational antisense medicine for treating Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations (FUS-ALS). The study will help determine the safety and effectiveness of the potential new treatment using the investigational antisense medicine ION363 for FUS-ALS, which is designed to target and stop the FUS gene from making its protein, which may improve symptoms of ALS.
Would you like to know more about the FUSION study?
